OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is a prospective, double-blind, placebo-controlled, randomized clinical trial to assess
the effects of daily 4-gram marine omega-3 polyunsaturated fatty acid (MO3PUFA), through
treatment with AMR101 (VASCEPA, icosapent ethyl) on the tumor immune microenvironment and gut
microbiome in patients who are diagnosed with colorectal cancer or with a colorectal mass or
polyp suspected to be a cancer or advanced adenoma and will undergo surgical resection or
interventional endoscopy at the Massachusetts General Hospital (MGH). It uses the novel
"window-of-opportunity" clinical trial design to take advantage of the window of time between
cancer/mass/polyp diagnosis and surgery to examine the effect of therapeutic agents on tumor
pathologic and molecular features unperturbed by prior therapies.
Phase:
Phase 2
Details
Lead Sponsor:
Mingyang Song
Collaborators:
Harvard School of Public Health Harvard School of Public Health (HSPH)